Market open

Veru/$VERU

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Veru

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.

Ticker

$VERU

Sector

Consumer Staples

Trading on

NASDAQ

Industry

Personal Care Products

Headquarters

Miami, United States

Employees

210

Website

verupharma.com

Veru Metrics

BasicAdvanced

$109M

-

-$0.28

-0.55

-

Price and volume

Market cap

$109M

Beta

-0.55

52-week high

$1.92

52-week low

$0.36

Average daily volume

1.6M

Financial strength

Current ratio

2.968

Quick ratio

2.433

Long term debt to equity

36.428

Total debt to equity

42.899

Interest coverage (TTM)

-62.78%

Management effectiveness

Return on assets (TTM)

-43.17%

Return on equity (TTM)

-145.40%

Valuation

Price to revenue (TTM)

5.938

Price to book

3.37

Price to tangible book (TTM)

4.28

Price to free cash flow (TTM)

-4.591

Growth

Revenue change (TTM)

3.62%

Earnings per share change (TTM)

-74.43%

3-year revenue growth (CAGR)

-34.92%

3-year earnings per share growth (CAGR)

46.03%

What the Analysts think about Veru

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Veru stock.

Veru Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Veru Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Veru News

AllArticlesVideos

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

GlobeNewsWire·2 weeks ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

GlobeNewsWire·2 months ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

GlobeNewsWire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VERU

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Veru stock?

Veru (VERU) has a market cap of $109M as of January 15, 2025.

What is the P/E ratio for Veru stock?

The price to earnings (P/E) ratio for Veru (VERU) stock is 0 as of January 15, 2025.

Does Veru stock pay dividends?

No, Veru (VERU) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Veru dividend payment date?

Veru (VERU) stock does not pay dividends to its shareholders.

What is the beta indicator for Veru?

Veru (VERU) has a beta rating of -0.55. This means that it has an inverse relation to market volatility.